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Solid cancer remains a major cause of death in the world. As limited treatment options are currently available to
patients with solid cancer, novel preventive control and effective therapeutic approaches are considered to be
reasonable and decisive measures to combat this disease. The plant-derived triterpenoids, commonly used for
medicinal purposes in many Asian countries, poses various pharmacological properties. A large number of
triterpenoids exhibit cytotoxicity against a variety of cancer cells, and cancer preventive, as well as anticancer
efficacy in preclinical animal models. To improve antitumor activity, some synthetic triterpenoid derivatives have
been synthesized, including cyano-3,12-dioxooleana-1,9(11)- dien-28-oic (CDDO), its methyl ester (CDDO-Me), and
imidazolide (CDDO-Im) derivatives. In this review, we will critically examine the current preclinical evidences of
cancer preventive and therapeutic activity about one of the synthetic triterpenoids, CDDO-Me. Both in vitro and
in vivo effects of this agent and related molecular mechanisms are presented.
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It has now become evident that cancer development
underlies a collection of multiple genetic abnormalities
through a multistep, mutagenic process [1,2]. The com-
plexity of the genetic lesions and the variation of the de-
rivative phenotypic changes of cancer cells indicate that
multifunctional drugs capable of affecting cancer cells at
various levels must be used for the treatment of these
diseases [3,4]. With this background, agents like triterpe-
noids that can alter multiple dysregulated cellular path-
ways may have a significant potential for solid cancer
prevention and treatment [5,6]. In this review, we will
critically examine the current preclinical evidences of
cancer preventive and therapeutic activity about one of the
synthetic triterpenoids, C-28 methyl ester of 2-cyano-3,12-
dioxoolean-1,9-dien-28-oic acid (CDDO-Me). Both in vitro
and in vivo effects of this agent and related molecular
mechanisms are presented.* Correspondence: shsyztd@sohu.com
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Triterpenoids are metabolites of isopentenyl pyrophosphate
oligomers and represent the largest group of phytochemi-
cals. It has been estimated that more than 20,000 triterpe-
noids exist in nature [7]. Triterpenoids are used medicinally
in many Asian countries for their anti-inflammatory,
analgesic, antipyretic, hepatoprotective, cardiotonic, seda-
tive and tonic effects [8,9]. An increasing number of triter-
penoids have been reported to exhibit cytotoxicity against
a variety of cancer cells without manifesting any toxicity
in normal cells. They also demonstrate antitumor efficacy
in preclinical animal models of cancer [4,10,11].
To improve antitumor activity, triterpenoid derivatives
have been synthesized. In 1999, one such synthetic triterpen-
oid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO),
which has been found to be 100–500 fold more potent than
any previous triterpenoids in suppressing inducible nitric
oxide synthase and cyclooxygenase 2 (COX-2) – two inflam-
matory enzymes having important roles in the development
of malignancy [12,13] , has been successfully developed [14].
In order to increase the potency of CDDO, various C-28
derivatives have been synthesized. CDDO-Me, one of the
derivatives of CDDO, has shown the effects of preventingtd. This is an Open Access article distributed under the terms of the Creative
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proliferative effect exerted by CDDO-Me in cancer cells
seems to be more potent than that induced by either C-28
imidazolide of CDDO (CDDO-Im) or CDDO itself [15].
CDDO-Me is one of the most potent activators of the
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway.
Biological response to CDDO-Me is dependent on dose.
Low concentrations (nanomolar) of CDDO-Me target
kelch-like ECH-associated protein 1 (Keap1) and activate
the Nrf2/ antioxidant responsive element (ARE) cytoprotec-
tive and anti-inflammatory response. As the concentration
of CDDO-Me increases, it targets Actin-related protein 3
(Arp3) and other components of the cytoskeleton to inhibit
cell proliferation, whereas even higher concentrations
(micromolar) of CDDO-Me can selectively induce apoptosis
in cancer cells by targeting a number of key regulatory
proteins and pathways that are frequently constitutively
activated or overexpressed in cancer cells [5].
In vivo cancer preventive effects of CDDO-Me
Anticarcinogenic activities of CDDO-Me have been estab-
lished in both chemical carcinogenesis models and trans-
genic mouse models of various cancers (Table 1).Table 1 In vivo solid cancer preventive effects of CDDO-Me
Effects Mechanisms
Decreased the average tumor burden of
vinyl carbamate-induced andenocarcinoma
in female A/J mice
Suppression of the ability of IFN-γ
de novo formation of NO synthas
of HO-1; Suppression of phospho
STAT3 as well as induction of apo
Prevented the formation of ER- negative
mammary tumors in the mouse mammary
tumor virus-neu transgenic model
Inhibited constitutive STAT3 phos
and the degradation of IKBα
Increased survival of the KPC mice by 3
to 4 weeks
Interacted with both STAT3 and IK
decrease constitutive IL-6 secretio
constitutive STAT3 phosphorylatio
blocked the degradation of IKBα w
challenged with TNF-α
Delayed ER–negative mammary
carcinogenesis in polyoma middle T Mice
Inhibited cyclin D1 and decrease
phosphorylation of EGFR and ST
Delayed tumor development in the
BRCA1-mutated mice by an average
of 5.2 weeks
Interacted with ErbB2, decreased
phosphorylation of ErbB2, inhibite
proliferation, and induced G0/G1
Inhibited the progression of preneoplastic
lesions in the DLP and VP lobes to
adenocarcinoma in TRAMP mice
Inhibited cell proliferation, reduc
density of blood vessels and pro
apoptosis in the prostatic tissue
Inhibited the progression of the
preneoplastic lesions to adenocarcinoma
in the DLP and VP lobes of TRAMP mice
Inhibited the expression of prosur
and NF-κB in the prostate
Inhibited the progression of preneoplastic
lesions to adenocarcinoma of the prostate
in TRAMP mice
Decreased TERT and its regulato
in the prostate
Akt: protein kinase B1; BRCA1:breast cancer-associated gene 1; DLP: dorsolateral prostate
epidermal growth factor receptor 2; HO-1: heme oxygenase-1; IKBα, inhibitor of nuclear f
LSL-Trp53R127H/+; Pdx-1-Cre; NF-κB: nuclear factor-κB; NO: nitric oxide; STAT3: transcription
transcriptase TNF-α: tumor necrosis factor α; TRAMP: transgenic adenocarcinoma of the mCDDO-Me is a potent inhibitor of lung carcinogenesis
in A/J mice. Liby et al. [16] looked at female A/J mice
treated with the mutagenic carcinogen vinyl carbamate,
which induces adenocarcinoma of the lung in all animals
within 16 weeks. If mice were fed either the CDDO-Me
or the CDDO ethyl amide (CDDO-Ea), beginning 1 week
after dosing with carcinogen, the number, size, and se-
verity of lung carcinomas were markedly reduced. The
triterpenoids CDDO-Ea and CDDO-Me reduced the
average tumor burden (ATB) in the lungs 86% to 92%,
respectively, compared with the controls, and the rexinoid
LG100268 reduced ATB by 50%.
Liby et al. [17] also investigated whether the CDDO-Me
and the rexinoid LG100268 could prevent the formation of
estrogen receptor (ER)-negative mammary tumors in the
mouse mammary tumor virus-neu transgenic model. Mice
were fed control diet, CDDO-Me, LG100268, or the com-
bination. CDDO-Me and LG100268 significantly delayed
the development of ER-negative tumors, with a 14- and 24-
week delay, respectively, compared with the control group
for the time required to reach 50% tumor incidence. The
combination of CDDO-Me and LG100268 was significantly





60 mg/kg, 2 weeks Diet [16]





60 mg/kg diet or 15 mg/kg body
weight. Beginning at 4 weeks of








50 mg/kg. Beginning at 12 weeks




10 μmol/kg. 20 weeks Oral gavage [21]
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; EGFR: epidermal growth factor receptor; ER: estrogen receptor; ErbB2: human
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factor signal transducers and activators of transcription 3; TERT: telomerase reverse
ouse prostate model; VP: ventral prostate.
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at which time all control animals had tumors. The same
group also found that CDDO-Me, LG100268, the combin-
ation of CDDO-Me and LG100268, and the combination of
CDDO-Ea and LG100268, all significantly increased the sur-
vival of the LSL-KrasG12D/+; LSL-Trp53R127H/+; Pdx-1-Cre
(KPC) mouse pancreatic cancer model by 3 to 4 weeks [18].
Tran et al. [19] tested the activity of CDDO-Me in
a relevant model of ER–negative breast cancer, the
polyoma-middle T (PyMT), in which the oncoprotein
drives carcinogenesis. Mice were fed CDDO-Me, starting
at 4 weeks of age. CDDO-Me significantly increased
the age of mice at onset of first tumor by an average of
4.3 weeks and overall survival by 5.2 weeks. The drug also
inhibited the infiltration of tumor-associated macrophages
into mammary glands of PyMT mice at 12 weeks of age
and reduced levels of the chemokines CXCL12 and CCL2
in primary PyMT mammary tumor cells. Treatment with
this multifunctional drug also inhibited secretion of matrix
metalloproteinase-9 in primary tumor cells from PyMT
mice and decreased proliferation of these cells by inhibit-
ing cyclin D1 and decreasing phosphorylation of epider-
mal growth factor receptor and signal transducer and
activator of transcription 3 (STAT3).
In a mouse model in which deletion of the BRCA1
gene (breast cancer associated gene 1) is combined with
a mutation in a single allele in the p53 tumor suppressor
gene, CDDO-Me significantly delays tumor development
[20]. Beginning at 12 weeks of age, Brca1Co/Co; MMTV-
Cre;p53+/− mice were fed powdered control diet or diet
containing CDDO-Me. CDDO-Me significantly delayed
tumor development in the BRCA1-mutated mice by an
average of 5.2 weeks. The authors also observed that levels
of ErbB2, pErbB2, and cyclin D1 increased in a time-
dependent manner in the mammary glands in BRCA1-
deficient mice, and CDDO-Me inhibited the constitutive
phosphorylation of ErbB2 in tumor tissues from these mice.
In BRCA1-deficient cell lines, the triterpenoids directly
interacted with ErbB2, decreased constitutive phosphoryl-
ation of ErbB2, inhibited proliferation, and induced G0/G1
arrest. These results suggest that CDDO-Me has the poten-
tial to prevent BRCA1-mutated breast cancer.
Deeb et al. reported that administration of CDDO-Me
to transgenic adenocarcinoma of the mouse prostate
(TRAMP) mice resulted in inhibition of progression of pre-
neoplastic lesions (low and high-grade prostate intraepithe-
lial neoplasms, PINs) to adenocarcinoma of the prostate in
more than 70% of the mice without noticeable toxicity
[21,22]. Subsequently, the same group also found that treat-
ment with CDDO-Me inhibited metastasis of cancer to
lung, liver, kidney and pelvic lymph nodes. The response to
CDDO-Me in TRAMP mice was associated with reduction
in proteins that regulate production and phosphorylation of
telomerase reverse transcriptase (TERT) [23].In vitro and in vivo anticancer effects of CDDO-me
In addition to its efficacy for prevention of cancer,
CDDO-Me has been used to treat established tumors
in experimental models (Table 2).
In vitro studies
Targeting nuclear factor kappa B (NF-κB) pathway
The NF-κB pathway is an important target of the CDDO-
me. NF-κB activates a number of genes that promote
inflammation, proliferation, and survival, and because
it regulates the inflammatory microenvironment, this
pathway can promote tumorigenesis [24,25]. Deeb et al. [26]
investigated the response of hormone-sensitive (LNCaP)
and hormone-refractory (PC-3 and DU145) human pros-
tate cancer cell lines to CDDO-Me. Their results demon-
strated that CDDO-Me could inhibit the growth of prostate
cancer cells. Detailed analysis of the antitumor activity of
CDDO-Me showed that it induced apoptosis in LNCaP
and PC-3 cells through activation of caspases 3, 8 and 9,
disruption of mitochondrial integrity, and inhibition of
anti-apoptotic B-cell lymphoma 2 (Bcl-2), B-cell lymphoma
extra large (Bcl-xL) and X-linked inhibitor of apoptosis pro-
tein (XIAP). Furthermore, induction of apoptosis was asso-
ciated with inhibition of the NF-κB signaling pathway.
Targeting phosphoinositide 3-kinase/ protein kinase B1/
mammalian target of rapamycin (PI3K/Akt/mTOR) pathway
Although the activation of the PI3K/Akt/mTOR pathway
may be beneficial in normal retinal epithelial cells or in
neurons to enhance survival, this pathway is often over-
expressed or activated in cancer cells [27]. Numerous
inhibitors of this pathway are being evaluated in clinical
trials for the treatment of cancer [28,29]. Deeb et al. [30]
determined the antitumor activity and the mechanism of
action of CDDO-Me for human prostate cancer cells.
CDDO-Me inhibited the growth and induced apoptosis
in PC-3 and C4-2 cells at extremely low concentrations.
The antitumor activity of CDDO-Me was associated with
the inhibition of p-Akt, mTOR and NF-κB signaling pro-
teins and their downstream targets. Silencing of Akt sensi-
tized the PC-3 cells to CDDO-Me, whereas overexpression
of Akt induced resistance to CDDO-Me. Targeted silencing
of Akt showed that Akt did not regulate mTOR activation
in PC-3 cells, but targeted silencing of mTOR sensitized
PC-3 cells to CDDO-Me mediated growth inhibition.
These data identified Akt and mTOR as molecular targets
of CDDO-Me in prostate cancer cells. In the subsequent
study [31], the same group also found that CDDO-Me
induced reactive oxygen species (ROS) generation. The
inhibition of ROS generation by N-acetylcysteine (NAC)
or by overexpression of antioxidant enzymes glutathione
peroxidase (GPx) and superoxide dismutase-1 (SOD-1) pre-
vented CDDO-Me-induced apoptosis. NAC also prevented
the inhibition of constitutively active Akt, NF-κB and
Table 2 In vitro anti-cancer effects of CDDO-Me on various solid cancer cells
Cellular effects Mechanisms Concentration Reference
Inhibited proliferation and induced apoptosis by in
LNCaP and PC-3 prostate cancer cell lines
Inhibited hTERT gene expression, hTERT telomerase activity
and a number of proteins that regulate hTERT
transcriptionally and posttranslationally
0.063-5 μM [23]
Inhibited the growth of LNCaP, PC-3 and DU145 prostate
cancer cells
Induced apoptosis through activation of caspases 3, 8 and
9, disruption of mitochondrial integrity, and inhibition of
anti-apoptotic Bcl-2, Bcl-xL and XIAP. Induction of
apoptosis was associated with the inhibition of
pro-survival Akt, mTOR, NF-κB signaling proteins
1.25-20 μM [26]
Inhibited the growth and induced apoptosis in PC-3 and
C4-2 prostate cancer cells
Inhibition of p-Akt, mTOR, and NF-κB signaling proteins
and their downstream targets such as p-Bad and p-Foxo3a
[Akt]; p-S6K1, p-eIF-4E and p-4E-BP1 [mTOR]; and COX-2,
VEGF and cyclin D1[NF-κB]
0.625-10 μM [30]
Inhibited the growth of both K-ras mutated and
wild-type K-ras pancreatic cancer cells
Inhibited of prosurvival p-Akt, NF-κB and mTOR signaling
proteins and the downstream targets of Akt and mTOR,
such as p-Foxo3a [Akt] and p-S6K1, p-eIF-4E and
p-4E-BP1 [mTOR]
0.625- 5 μM [32]
Inhibited the growth of colorectal cancer cells Suppressed pro-survival Akt, NF-κB and mTOR signaling
proteins and NF-κB-regulated anti-apoptotic Bcl-2, Bcl-xL,
Bad and survivin
1.25-10 mM [34]
Inhibited the growth of human ovarian cancer cell lines
OVCAR-3, OVCAR-5 and SK-OV3 and ovarian
endometrioid adenocarcinoma cell line MDAH-2774
Inhibition of Akt/ NF-κB /mTOR signaling pathway 0.625-10 μM [36]
CDDO-Me caused the generation of ROS and
pre-treatment with NAC prevented the generation
of ROS in OVCAR-5 and MDA 2774 ovarian cancer cells
ROS played a pivotal role in the anti-proliferative and
apoptosis-inducing activity of CDDO-Me in ovarian
cancer cells
1.25–10 μM [37]
Induced the apoptosis of glioblastoma [U87MG, U251MG]
and neuroblastoma [SK-N-MC] cell lines
Inhibited the levels of anti-apoptotic and prosurvival p-Akt,
NF-κB and Notch1 signaling molecules
2.5–10 μM [38]
Reversed the resistant of paclitaxel-resistant ovarian
cancer cell line OVCAR8TR and cisplatin-resistant ovarian
cancer cell line A2780cp70
Inhibited IL-6 secretion, STAT3 phosphorylation, STAT3
nuclear translocation
0.3 μM [42]
Reversed the resistant of MDR osteosarcoma cell lines
KHOSR2, U-2OSTR
Inhibited STAT3 phosphorylation, STAT3 nuclear
translocation and induced apoptosis
0.1; 0.3 μM [43]
Activated the extrinsic DR-mediated apoptotic pathway
in human lung cancer cells
Induced a JNK-dependent up-regulation of DR5
expression, leading to activation of caspase-8 and
induction of apoptosis
0.25-1 μM [47]
Induced JNK-dependent DR5 expression in human
lung cancer cells
Depleted intracellular GSH, resulting in ER stress.
Subsequently, it activated JNK, leading to
CHOP-dependent DR5 up-regulation and apoptosis
0.1-2 μM [48]
Induced apoptosis in human lung cancer cells A549
and H157
Induced apoptosis through downregulation of c-FLIP
Enhanced TRAIL-induced apoptosis
0.25;0.5;1 μM [49]
Inhibited proliferation and induced apoptosis in MiaPaCa-2
and Panc-1 human pancreatic cancer cell lines
Inhibited hTERT gene expression, hTERT telomerase
activity and a number of proteins that regulate
hTERT expression and activity
1.25–5 μM [54]
Induced apoptosis in MiaPaCa-2 and Panc-1 human
pancreatic cancer cell lines
Generated ROS and inhibited the telomerase activity 1.25 μM [55]
Inhibited MC38 colon carcinoma, Lewis lung carcinoma,
and EL-4 thymoma mouse tumor lines
Blocked ROS production, decreased levels of peroxynitrite
and abrogated MDSC suppressive activity against
antigen-specific CD8+ T cells
>1 μM [56]
Akt: protein kinase B1;Bad: Bcl-2-associated death promoter; Bcl-2:B-cell lymphoma 2; BCL-xL: B-cell lymphoma extra large; c-FLIP: cellular FLICE inhibitory protein;
CHOP: CCAAT/enhancer binding protein homologous protein; COX-2: cyclooxygenase 2; DR:death receptor; ER: endoplasmic reticulum; GSH: glutathione; hTERT:
human telomerase reverse transcriptase; JNK: c-Jun NH2-terminal kinase; MDR: multidrug resistant; MDSC: myeloid-derived suppressor cells; mTOR :mammalian
target of rapamycin; NAC: N-acetylcysteine; NF-κB: nuclear factor-κB; ROS: reactive oxygen species; STAT3: transcription factor signal transducers and activators of
transcription 3; TRAIL :TNF related apoptosis inducing ligand; VEGF: vascular endothelial growth factor; XIAP: X-linked inhibitor of apoptosis protein.
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pathway may be a ROS dependent manner. Similar antitu-
mor effect and mechanism of CDDO-Me also reportedin pancreatic cancer cells [32,33], colorectal cancer cells
[34,35], ovarian cancer cells [36,37], human glioblastoma
and neuroblastoma cell lines [38].
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STATs are transcription factors known to contribute to
cellular transformation, proliferation, survival, invasion,
and metastasis, and STAT3 is constitutively activated in
many types of cancers. After ligand binding to growth fac-
tor receptors, such as the interleukin 6 (IL-6) receptor, a
JAK phosphorylates the receptor, allowing recruitment and
phosphorylation of a STAT. STATs then dimerize, translo-
cate to the nucleus, and induce transcription of numerous
STAT targets, including cyclin D1, myc, and survivin pro-
teins [39,40]. By directly interacting with Cys1077 on JAK1,
CDDO-Me not only suppresses JAK1 phosphorylation but
also inhibits its ability to phosphorylate STAT3 and induce
STAT3 dimerization [41]. As both JAK and Src activation
could induce STAT3 activation, inhibition of JAK2 or Src
is another mechanism for CDDO-Me-mediated inhibition
of STAT3 phosphorylation and nuclear translocation.
In accordance with this mechanism, CDDO-Me can re-
verse the multi-drug resistant of ovarian cancer cells [42].
Similar anti-tumor effects and mechanism of CDDO-me
are also found in osteosarcomas cancer cells [43].
Targeting death receptor (DR) induced extrinsic
apoptotic pathway
It is well known that there are two major apoptotic path-
ways: the intrinsic mitochondria mediated pathway and the
extrinsic DR induced pathway [44]. Several studies have
demonstrated that CDDO-Me activates both intrinsic and
extrinsic apoptotic pathways [45-47]. However, the DR5
related extrinsic apoptotic pathway has been extensively
evaluated. Zou et al. showed that CDDO-Me induced DR5
up-regulation, which contributes to CDDO-Me induced
apoptosis and enhancement of tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL)-induced apop-
tosis in human non-small cell lung cancer (NSCLC) cells
[47]. CDDO-Me depleted intracellular glutathione (GSH),
resulting in endoplasmic reticulum stress. Subsequently,
it activated c-Jun NH2-terminal kinase (JNK), leading to
CCAAT/enhancer binding protein homologous protein
(CHOP)-dependent DR5 up-regulation and apoptosis [48].
After that, they further showed that, in addition to DR5
induction, CDDO-Me down-regulated cellular FLICE-
inhibitory protein (c-FLIP) levels in human NSCLC cells
though JNK-independent ubiquitin/proteasome-mediated
degradation of c-FLIP. c-FLIP is a key regulatory protein
that inhibits activation of the DR induced extrinsic apop-
totic pathway. These studies provide compelling evidence
for the involvement of the activation of the DR induced
extrinsic apoptotic pathway in CDDO-Me-induced apop-
tosis in human NSCLC cells [49].
Targeting telomere and/or telomerase
Telomeres, the nucleoprotein structures present at the
end of chromosomes, play a critical role in maintainingchromosome stability by preventing loss of telomeric
repeats, end-to-end fusion and chromosomal rearrange-
ment [50]. Telomeres shorten progressively during normal
cell division due to a gradual loss of telomeric DNA
sequence (TTAGGG) in each replication cycle [51,52].
When telomere length becomes critically short, it triggers
replicative senescence or apoptosis. Maintaining telomere
length is the function of telomerase (TERT), a ribonucleo-
protein polymerase that adds the hexameric DNA repeats
(TTAGGG) to the 3’flanking end of DNA strands in the
telomere. Deregulated telomerase activity is associated
with promotion of tumorigenesis and neoplastic growth of
human cancers [53]. Deeb et al. [54] showed that inhibition
of proliferation and induction of apoptosis in pancreatic
cancer cells by CDDO-Me involved the inhibition of
telomerase activity. CDDO-Me inhibited human TERT
gene expression, human TERT protein and human TERT
telomerase activity. Further, CDDO-Me also inhibited
human TERT regulatory proteins such as c-Myc, specificity
protein (Sp)1, NF-κB, p-STAT3 and p-Akt. Thus, targeting
the telomere and/or telomerase with CDDO-Me is a prom-
ising strategy for the treatment of pancreatic cancer. Subse-
quently, they investigated the role of ROS in inhibition
of telomerase by CDDO-Me. Treatment of MiaPaCa-2 and
Panc-1 pancreatic cancer cell lines with CDDO-Me in-
duced the production of hydrogen peroxide and superoxide
anions and inhibited the telomerase activity. Pretreatment
of cells with NAC, a general purpose antioxidant, or
overexpression of GPx or SOD-1 blocked the telomerase
inhibitory activity of CDDO-Me. Furthermore, blocking
ROS generation also prevented the inhibition of TERT gene
expression, protein production and expression of a number
of human TERT–regulatory proteins by CDDO-Me. They
concluded that inhibition of telomerase activity by CDDO-
Me was mediated through a ROS-dependent mechanism
[55]. However, the titration effect and direct interaction be-
tween CDDO-Me and NAC should be considered when
interpreting the results of these studies. Similar anti-tumor
effect and mechanism of CDDO-Me also found in prostate
cancer cells [23] and ovarian cancer cells [37].
Targeting immune cells
Nagaraj et al. [56] reported that CDDO-Me could block
immune suppressive function of myeloid-derived sup-
pressor cells (MDSC) and improve immune response
of solid tumor. MDSC promote tumor angiogenesis,
invasion and suppress T cell mediated immunosup-
pression of cancer cells [57,58]. They evaluated the ef-
fect of the CDDO-Me in MC38 colon carcinoma and
Lewis lung carcinoma. They found that CDDO-Me
completely abrogated immune suppressive activity of
MDSC in vitro. CDDO-Me reduced ROS in MDSC but
did not affect their viability or the levels of nitric oxide
and arginase. CDDO-Me may favorably improve antitumor
Wang et al. Molecular Cancer 2014, 13:30 Page 6 of 8
http://www.molecular-cancer.com/content/13/1/30immune function, especially when combined with a can-
cer vaccine.
In vivo studies
Whether CDDO-Me inhibits tumor growth in vivo was
examined in PC-3 prostate cancer xenograft model system
[30]. 2 × 106 PC-3 cells in 50 ml of medium mixed with
50 ml of matrigel were injected subcutaneous in the flank
of BALB/c nude mice. On day 8, tumor dimensions were
measured with a caliper and CDDO-Me treatment started.
In the treatment group, mice were gavaged daily with
10 μmol/kg CDDO-Me in 0.1 ml of vehicle consisting
of cremaphor EL:DMSO:PBS (1:1:8), 5 days a week for
5 weeks. In the control group, mice were gavaged with
vehicle without CDDO-Me. Tumors in the vehicle control
group progressively increased in size over a period of
6 weeks and one mouse was terminated on day 39 because
of large tumor size. In the CDDO-Me treatment group,
after an initial increase in tumor size for about 2 weeks,
tumors began to shrink and decreased in size. After 5 weeks
of treatment with CDDO-Me, the average tumor size was
significantly less than the size on the day treatment was
started. On day 50, the experiment was terminated and tu-
mors were harvested and weighed. Tumors of mice treated
with CDDO-Me weighed significantly less than those of the
untreated mice. These data demonstrated significant antitu-
mor activity of CDDO-Me in vivo.
Jutooru et al. investigated the in vivo anticancer activity
of CDDO-Me in an orthotopic model of pancreatic cancer
in which L3.6pL cells were injected directly into the
pancreas of 8- to 12-week-old male thymic nude mice.
Treatment with CDDO-Me (7.5 mg/kg/day) was initiated
7 days after injection of the cells and continued for an add-
itional 28 days. Treatment with CDDO-Me significantly de-
creased pancreatic tumor volume and weight compared
with the vehicle control group. In addition, lysate from
tumors treated with the vehicle or CDDO-Me were
also analyzed by western blots, and there was a marked
decrease in expression of Sp1, Sp3, and Sp4 proteins in
tumors from mice treated with CDDO-Me compared
with the control group. Moreover, expression of vascular
endothelial growth factor (VEGF), cyclin D1, and survivin
in tumors from CDDO-Me-treated mice were decreased
compared with animals receiving vehicle control [59].
In an immunocompetent mouse model of breast cancer,
chemoresistant 4 T1 cells, derived from a spontaneous
mammary tumor, were injected back into BALB/c mice
to study primary tumors as well as metastases. CDDO-
Me at 200 μg per mouse was given intravenous at 2-day
intervals. When treatment with CDDO-Me in liposomes
was started 1 day after the injection of 4 T1 cells, the
drug completely blocked tumor formation and metasta-
sis. Tumor size was also significantly smaller in the mice
treated with CDDO-Me than in the control group, evenwhen treatment was delayed until 5 days after inoculation
of the aggressive 4 T1 cells. Moreover, the population of
mature dendritic cells in BALB/c mice with 4 T1 tumors
decreases by two thirds compared with BALB/c mice with-
out tumors, but CDDO-Me helped maintain the number of
mature dendritic cells in this model. CDDO-Me not only
inhibited the invasion of 4 T1 breast cancer cells into a
matrix, but also eliminated metastasis to the lungs when
these cells are injected into BALB/c mice [60].
MMTV-neu mice were used to test whether CDDO-Me
and the rexinoid LG100268 prevent the formation of
ER-negative mammary tumors, or either arrest the growth
or cause regression of established tumors. Mice with tu-
mors at least 4 mm in diameter were fed control diet,
CDDO-Me (100 mg/kg diet), LG100268 (60 mg/kg diet), or
the combination for 4 weeks. Treating established tumors
with CDDO-Me arrested the growth of 86% of the tumors,
and LG100268 induced tumor regression in 85% of tu-
mors. CDDO-Me and LG100268 targeted different sig-
naling pathways and cell types. CDDO-Me inhibited
constitutive STAT3 phosphorylation and the degradation of
IKBa in ER-negative breast cancer cells, whereas LG100268
blocked IKBa degradation and the release of IL-6 in
RAW264.7 macrophage-like cells, inhibited the ability of
endothelial cells to organize into networks, and blocked
angiogenesis in vivo [17].
There are undoubtedly other targets and pathways that
account for the effects of CDDO-Me on established can-
cers, but new mechanistic studies will require additional
experiments and analysis in relevant animal models.
Clinical trials
Most of the experimental evidence favors further develop-
ment of the triterpenoid CDDO-Me as a potential agent for
prevention and treatment of cancer. Clinical trials should
be carried out to test the potential efficacy of this drug
in solid cancer treatment.
Nagaraj et al. [56] analyzed samples from 19 patients
with pancreatic adenocarcinoma that were treated in the
phase I clinical trial RTA 402-C-0702. Patients were treated
intravenously with gemcitabine (1,000 mg/m2) weekly
on days 1, 8, and 15. CDDO-Me was administered orally
once daily for 21 days. Nine patients received a dose of
150 mg/d; 2 patients, 200 mg/d; 6 patients, 250 mg/d; and
2 patients, 300 mg/d. No toxicity attributed to CDDO-Me
was observed. Treatment of pancreatic cancer patients
with CDDO-Me did not affect the number of MDSCs
in peripheral blood, but significantly improved the im-
mune response.
Hong et al. [61] established a phase I clinical trial which
aimed to determine the dose-limiting toxicities (DLT),
maximum tolerated dose (MTD), and appropriate dose
for phase II studies; to characterize pharmacokinetic and
pharmacodynamics parameters; and to assess antitumor
Wang et al. Molecular Cancer 2014, 13:30 Page 7 of 8
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transaminase elevation. The MTD was established as
900 mg/d. A complete tumor response occurred in a
mantle cell lymphoma patient, and a partial response
was observed in an anaplastic thyroid carcinoma patient.
NAD(P)H dehydrogenase, quinone 1 (NQO1) mRNA levels
increased in peripheral blood mononuclear cells, and
NF-κB and cyclin D1 levels decreased in tumor biopsies.
They concluded that CDDO-Me was well tolerated with
an MTD of 900 mg/d. For the observed objective tumor
responses, other synthetic triterpenoids were suggested
for continued development in solid cancer treatment.
Conclusions
There has been substantial evidence supporting the
preventive effect of CDDO-Me in a number of in vivo
studies. There is also convincing evidence in laboratory
studies and clinical trials in support of the antitumor effects
of CDDO-Me in several cancers, with inhibition of tumor
cell growth mainly by modulation of pathways that con-
tribute to cell proliferation and apoptosis. Nevertheless, a
considerable amount of work remains to be done, such as
identification of novel target proteins and intercellular
pathways in which they function, and development of
selective end points and surrogate biomarkers for evaluat-
ing efficacy. Long standing epidemiological studies and
well-designed clinical trials are also necessary.
In summary, the in vitro and in vivo data examined in
this review strongly suggests that triterpenoid CDDO-Me
is a promising candidate for the preventive and treatment
of solid cancer.
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